← Home / CRISPR THERAPEUTICS AG (CRSP)
Stock Analysis
CRISPR THERAPEUTICS AG (CRSP)
CRSP
CRSP · Healthcare • Biotech
47.97 -0.97%
Track CRSP in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when CRSP price is:
52W Range Position
11%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-07-31 15:47 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
51.38
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
4
●
Management / Board
MEDIUM
CRSP board and management update
The 2026 Plan will reserve the remaining number of shares reserved for issuance under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan (the “2018 Plan”) on the effective date of the 2026 Plan, plus any common shares underlying any awards that are forfeited, canceled or are otherwise terminated, other...
8-K Filing • SEC EDGAR
MAY
4
●
Financial Results
HIGH
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.
8-K Filing • SEC EDGAR
What's Driving CRSP?
📈 Technical recovery is improving
Momentum is Neutral. Watch 51.38 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
41.6
Price Chart
CRSP — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-30
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$4.7B
Company size
EV
$4.8B
Debt-adjusted value
P/E
-8.2
Not meaningful
P/B
2.6
Balanced
EV/EBIT
-7.5
Not meaningful
P/FCF
-11.6
Not meaningful
FCF Yield
-8.59%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Recovering
⚖
Balance Sheet
Strong
💵 Revenue
1.46M
↗ Strong
📈 Net Income
-122.93M
↘ Negative
🧮 EPS (Basic)
-1.28
↘ Negative
CRISPR THERAPEUTICS AG
Healthcare • Biotech
Related Opportunities